1. Home
  2. NUVL vs DUOL Comparison

NUVL vs DUOL Comparison

Compare NUVL & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$105.83

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Duolingo Inc.

DUOL

Duolingo Inc.

HOLD

Current Price

$148.99

Market Cap

8.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
DUOL
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
8.4B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
NUVL
DUOL
Price
$105.83
$148.99
Analyst Decision
Strong Buy
Buy
Analyst Count
15
17
Target Price
$135.00
$281.00
AVG Volume (30 Days)
548.0K
1.7M
Earning Date
02-26-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
338.81
EPS
N/A
8.04
Revenue
N/A
$964,271,000.00
Revenue This Year
N/A
$40.50
Revenue Next Year
N/A
$22.55
P/E Ratio
N/A
$18.69
Revenue Growth
N/A
39.86
52 Week Low
$55.54
$147.70
52 Week High
$112.88
$544.93

Technical Indicators

Market Signals
Indicator
NUVL
DUOL
Relative Strength Index (RSI) 54.70 27.23
Support Level $97.43 $169.63
Resistance Level $108.65 $179.01
Average True Range (ATR) 4.95 7.56
MACD 0.48 -1.88
Stochastic Oscillator 82.96 1.77

Price Performance

Historical Comparison
NUVL
DUOL

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About DUOL Duolingo Inc.

Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.

Share on Social Networks: